Drug Profile
MK 0773
Alternative Names: MK-0773Latest Information Update: 12 Jun 2019
Price :
$50
*
At a glance
- Originator GTx
- Developer Merck & Co
- Class Azasteroids; Osteoporosis therapies; Small molecules
- Mechanism of Action Selective androgen receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Sarcopenia
Most Recent Events
- 07 Jun 2019 GTx has merged with Oncternal Therapeutics to form Oncternal Therapeutics
- 17 Mar 2010 GTx and Merck terminate licensing agreement
- 18 Jun 2008 Pharmacodynamics and safety data from a phase I trial in healthy postmenopausal women presented at The Endocrine Society's 90th Annual Meeting (ENDO-2008)